vs
美国合众银行（EBMT）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是美国合众银行的1.5倍（$35.5M vs $24.3M），美国合众银行净利率更高（19.5% vs -304.2%，领先323.7%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 13.7%），美国合众银行自由现金流更多（$28.3M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 12.6%）
美国合众银行是一家美国跨国银行金融机构，总部位于明尼苏达州明尼阿波利斯，在特拉华州注册成立。截至2025年，它是美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的金融机构，主营银行、投资、抵押贷款等金融业务。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
EBMT vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.5倍
$24.3M
营收增速更快
RXRX
高出668.0%
13.7%
净利率更高
EBMT
高出323.7%
-304.2%
自由现金流更多
EBMT
多$75.7M
$-47.3M
两年增速更快
RXRX
近两年复合增速
12.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $24.3M | $35.5M |
| 净利润 | $4.7M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 25.0% | -304.8% |
| 净利率 | 19.5% | -304.2% |
| 营收同比 | 13.7% | 681.7% |
| 净利润同比 | 37.8% | 39.6% |
| 每股收益（稀释后） | $0.62 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBMTRXRX
| Q4 25 | $24.3M | $35.5M | ||
| Q3 25 | $23.4M | $5.2M | ||
| Q2 25 | $23.0M | $19.2M | ||
| Q1 25 | $20.9M | $14.7M | ||
| Q4 24 | $21.4M | $4.5M | ||
| Q3 24 | $20.8M | $26.1M | ||
| Q2 24 | $19.9M | $14.4M | ||
| Q1 24 | $19.2M | $13.8M |
净利润EBMTRXRX
| Q4 25 | $4.7M | $-108.1M | ||
| Q3 25 | $3.6M | $-162.3M | ||
| Q2 25 | $3.2M | $-171.9M | ||
| Q1 25 | $3.2M | $-202.5M | ||
| Q4 24 | $3.4M | $-178.9M | ||
| Q3 24 | $2.7M | $-95.8M | ||
| Q2 24 | $1.7M | $-97.5M | ||
| Q1 24 | $1.9M | $-91.4M |
毛利率EBMTRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率EBMTRXRX
| Q4 25 | 25.0% | -304.8% | ||
| Q3 25 | 21.2% | -3327.6% | ||
| Q2 25 | 17.4% | -916.8% | ||
| Q1 25 | 18.5% | -1297.9% | ||
| Q4 24 | 17.3% | -4042.4% | ||
| Q3 24 | 15.6% | -377.1% | ||
| Q2 24 | 11.0% | -697.4% | ||
| Q1 24 | 11.8% | -698.4% |
净利率EBMTRXRX
| Q4 25 | 19.5% | -304.2% | ||
| Q3 25 | 15.5% | -3135.3% | ||
| Q2 25 | 14.1% | -894.2% | ||
| Q1 25 | 15.5% | -1373.3% | ||
| Q4 24 | 16.1% | -3935.5% | ||
| Q3 24 | 13.0% | -367.5% | ||
| Q2 24 | 8.7% | -676.6% | ||
| Q1 24 | 9.9% | -662.4% |
每股收益（稀释后）EBMTRXRX
| Q4 25 | $0.62 | $-0.17 | ||
| Q3 25 | $0.46 | $-0.36 | ||
| Q2 25 | $0.41 | $-0.41 | ||
| Q1 25 | $0.41 | $-0.50 | ||
| Q4 24 | $0.44 | $-0.56 | ||
| Q3 24 | $0.34 | $-0.34 | ||
| Q2 24 | $0.22 | $-0.40 | ||
| Q1 24 | $0.24 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.0M | $743.3M |
| 总债务越低越好 | $44.5M | $9.6M |
| 股东权益账面价值 | $191.8M | $1.1B |
| 总资产 | $2.1B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.23× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资EBMTRXRX
| Q4 25 | $63.0M | $743.3M | ||
| Q3 25 | $29.5M | $659.8M | ||
| Q2 25 | $26.9M | $525.1M | ||
| Q1 25 | $22.8M | $500.5M | ||
| Q4 24 | $31.6M | $594.4M | ||
| Q3 24 | $42.2M | $427.6M | ||
| Q2 24 | $23.8M | $474.3M | ||
| Q1 24 | $20.9M | $296.3M |
总债务EBMTRXRX
| Q4 25 | $44.5M | $9.6M | ||
| Q3 25 | $59.3M | $11.9M | ||
| Q2 25 | $59.2M | $14.2M | ||
| Q1 25 | $59.2M | $16.4M | ||
| Q4 24 | $59.1M | $19.0M | ||
| Q3 24 | $59.1M | $20.5M | ||
| Q2 24 | $59.1M | $22.9M | ||
| Q1 24 | $59.0M | — |
股东权益EBMTRXRX
| Q4 25 | $191.8M | $1.1B | ||
| Q3 25 | $186.5M | $1.0B | ||
| Q2 25 | $180.6M | $919.1M | ||
| Q1 25 | $177.6M | $933.9M | ||
| Q4 24 | $174.8M | $1.0B | ||
| Q3 24 | $177.7M | $524.6M | ||
| Q2 24 | $170.2M | $584.4M | ||
| Q1 24 | $168.9M | $401.2M |
总资产EBMTRXRX
| Q4 25 | $2.1B | $1.5B | ||
| Q3 25 | $2.1B | $1.4B | ||
| Q2 25 | $2.1B | $1.3B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | $2.1B | $1.4B | ||
| Q3 24 | $2.1B | $726.5M | ||
| Q2 24 | $2.1B | $775.9M | ||
| Q1 24 | $2.1B | $557.8M |
负债/权益比EBMTRXRX
| Q4 25 | 0.23× | 0.01× | ||
| Q3 25 | 0.32× | 0.01× | ||
| Q2 25 | 0.33× | 0.02× | ||
| Q1 25 | 0.33× | 0.02× | ||
| Q4 24 | 0.34× | 0.02× | ||
| Q3 24 | 0.33× | 0.04× | ||
| Q2 24 | 0.35× | 0.04× | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.1M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $28.3M | $-47.3M |
| 自由现金流率自由现金流/营收 | 116.7% | -133.1% |
| 资本支出强度资本支出/营收 | 19.7% | 3.5% |
| 现金转化率经营现金流/净利润 | 7.01× | — |
| 过去12个月自由现金流最近4个季度 | $37.1M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流EBMTRXRX
| Q4 25 | $33.1M | $-46.1M | ||
| Q3 25 | $9.0M | $-117.4M | ||
| Q2 25 | $1.7M | $-76.4M | ||
| Q1 25 | $1.9M | $-132.0M | ||
| Q4 24 | $28.5M | $-115.4M | ||
| Q3 24 | $2.6M | $-59.2M | ||
| Q2 24 | $3.3M | $-82.2M | ||
| Q1 24 | $7.1M | $-102.3M |
自由现金流EBMTRXRX
| Q4 25 | $28.3M | $-47.3M | ||
| Q3 25 | $7.1M | $-117.6M | ||
| Q2 25 | $1.4M | $-79.6M | ||
| Q1 25 | $262.0K | $-133.8M | ||
| Q4 24 | $14.5M | $-116.7M | ||
| Q3 24 | $-749.0K | $-63.8M | ||
| Q2 24 | $627.0K | $-83.4M | ||
| Q1 24 | $2.3M | $-109.0M |
自由现金流率EBMTRXRX
| Q4 25 | 116.7% | -133.1% | ||
| Q3 25 | 30.3% | -2272.5% | ||
| Q2 25 | 6.0% | -413.9% | ||
| Q1 25 | 1.3% | -907.4% | ||
| Q4 24 | 67.7% | -2567.7% | ||
| Q3 24 | -3.6% | -244.6% | ||
| Q2 24 | 3.2% | -578.5% | ||
| Q1 24 | 12.2% | -789.9% |
资本支出强度EBMTRXRX
| Q4 25 | 19.7% | 3.5% | ||
| Q3 25 | 8.0% | 4.7% | ||
| Q2 25 | 1.6% | 16.4% | ||
| Q1 25 | 7.8% | 12.4% | ||
| Q4 24 | 65.9% | 28.6% | ||
| Q3 24 | 16.1% | 17.5% | ||
| Q2 24 | 13.3% | 8.2% | ||
| Q1 24 | 24.9% | 48.2% |
现金转化率EBMTRXRX
| Q4 25 | 7.01× | — | ||
| Q3 25 | 2.47× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 8.31× | — | ||
| Q3 24 | 0.96× | — | ||
| Q2 24 | 1.88× | — | ||
| Q1 24 | 3.75× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBMT
| Other | $13.2M | 54% |
| Commodity Sales | $8.6M | 35% |
| Bank Servicing | $2.6M | 11% |
RXRX
暂无分部数据
